Development and clinical application of high-sensitive focused DNA array
| Project/Area Number |
15591437
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Saitama Medical School |
|---|
Principal Investigator |
ICHIKAWA Wataru Saitama Medical School, Medicine, Associate professor, 医学部, 助教授 (70282738)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
北郷 邦昭 埼玉医科大学, 医学部, 講師 (00161472)
平山 廉三 埼玉医科大学, 医学部, 教授 (10014317)
|
|---|
| Project Period (FY) |
2003 – 2005
|
| Project Status |
Completed (Fiscal Year 2005)
|
| Budget Amount *help |
¥3,800,000 (Direct Cost: ¥3,800,000)
Fiscal Year 2005: ¥500,000 (Direct Cost: ¥500,000)
Fiscal Year 2004: ¥700,000 (Direct Cost: ¥700,000)
Fiscal Year 2003: ¥2,600,000 (Direct Cost: ¥2,600,000)
|
|---|
| Keywords | DNA array / 5-FU / prediction / northern hybridization |
|---|
| Research Abstract |
In this study, we successfully developed high-sensitive focused DNA array (FDA) and applied this FDA to predict the clinical outcome in patients treated with fluoropyrimidine-based chemotherapy.
1)Development of Focused DNA array :
We made the probes for specific targeted DNA to obtain high specificity, and prepared the spotting dose of the targeted DNA for high sensitivity, in 52 genes involving 5-fluorouracil pathway.
2)Validation study
We validated the sensitivity and specificity of this FDA in various cancer cell lines by the comparison with the results of northern hybridization.
We selected 34 5-FU pathway genes from all 52 genes, which correlated with 5-FU sensitivity determined by histo-drug culture assay (HDRA) using clinical samples.
3)Clinical application
We selected 26 genes and 16 genes to predict the clinical outcome in gastric and colorectal cancer patients, respectively, with the accuracy rates of 82% and 100% for survival.
In the validation set including independent cohorts, the accuracy rates of survival were 74% and 94% in gastric and colorectal cancer patients.
In conclusion, our developed FDA with high sensitivity and specificity might be a useful tool to predict the clinical outcome in patients treated with fluoropyrimidine-based chemotherapy.
|
Report
(4 results)
Research Products
(17 results)
